RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States
Brogan, A., Talbird, S., Thompson, JR., Kim, YA., Olson, J., Peterson, J., Piontkowsky, D., & Pietrandoni, G. (2013). Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States. Value in Health, 16(7), A343-A344.